Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre Phase II Randomised Controlled Trial to Evaluate the Efficacy of Adaptive Therapy (AT) With Carboplatin, Based on Changes in CA125, in Patients With Relapsed Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer

NCT05080556 is registered in ClinicalTrials.gov with University College, London as lead sponsor.

NCT NCT05080556
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05080556 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre Phase II Randomised Controlled Trial to Evaluate the Efficacy of Adaptive Therapy (AT) With Carboplatin, Based on Changes in CA125, in Patients With Relapsed Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer
Lead sponsor
University College, London
Phase
Phase 2
Overall status
Recruiting
Start date
May 24, 2023
Completion date
November 1, 2027
Enrollment
80 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

endometrioid carcinoma, fallopian tube cancer, high grade serous carcinoma, ovarian cancer, ovary cancer, peritoneal cancer, relapsed ovarian cancer